Wanbury Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Excellent return on equity (ROE 76.5%)
- Efficient capital deployment (ROCE 36.6%)
- Attractively valued vs sector (P/E 16.1x vs industry 50.2x)
- Near 52-week low — potential value zone (₹162)
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
WANBURY · as of Jun 2026
| Category | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 39.79% | 39.79% | 39.77% | 39.76% | 39.76% | 39.63% |
| FII | 0.18% | 0.22% | 1.02% | 0.84% | 1.55% | 1.59% |
| Public | 60.02% | 59.97% | 59.21% | 59.40% | 58.68% | 58.79% |
Latest News
All newsWanbury wins approvals for Tanuku, Patalganga facilities
*Wanbury wins approvals for Tanuku, Patalganga facilities* — The company announced regulatory awards for its manufacturing facilities at Tanuku and Patalganga. This paves the way for expanded production capacity and potential revenue growth. The development is positive for long-term operations. 📊 *STOCKS:* $WANBURY | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Pharma
Wanbury announces regulatory progress and new business opportunities
*Wanbury announces regulatory progress and new business opportunities* — The company shared updates on its API business, citing regulatory approvals and new business prospects. Operational achievements were highlighted, with potential for near-term revenue contributions. No financial figures were disclosed. 📊 *STOCKS:* $WANBURY | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Pharma
Wanbury's subsidiary launches berrysoft baby range in India
*Wanbury's subsidiary, Wanbury Skin Health, launched its berrysoft baby product range across multiple Indian states.* This marks a strategic entry into the paediatric dermatology segment. The move expands its presence in the growing skincare market. 📊 *STOCKS:* WANBURY | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #ProductLaunch
Wanbury to hold 38th AGM via video conferencing
*Wanbury to hold 38th AGM via video conferencing.* The company will conduct its **38th Annual General Meeting** through Video Conferencing or Other Audio Visual Means. Details are part of a routine corporate filing with the NSE. No financial or operational updates were provided. 📊 *STOCKS:* $WANBURY | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AGM
Wanbury shares unchanged after newspaper publication filing
*Wanbury shares unchanged after newspaper publication filing.* The company submitted a copy of its newspaper publication as part of regulatory compliance. No financial or operational updates were disclosed. Such filings are routine and do not impact business operations. 📊 *STOCKS:* $WANBURY | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Filing